在早期乳腺癌辅助治疗中最大化蒽环类药物联合紫杉类药物的临床获益
本文通过两例早期乳腺癌病例展示辅助化疗决策中的诊断与管理挑战,并综述相关文献。作者总结了蒽环类药物联合紫杉类在辅助治疗中临床获益的推荐管理方法,以帮助读者将关键研究结果应用于临床实践。
要点
- 两例早期乳腺癌患者均接受多学科肿瘤委员会推荐的辅助化疗、术后放疗和内分泌治疗。
- 第一例为56岁绝经后女性,左乳3.5cm浸润性导管癌,11枚腋窝淋巴结中2枚转移,ER阳性50%、PR阴性、Ki-67 60%、HER2无扩增。
- 第二例为52岁绝经后女性,右乳2.5cm浸润性导管癌,3枚前哨淋巴结均无转移,ER阳性90%、PR阳性40%、Ki-67 20%、HER2无扩增,基因组检测提示中至高复发风险。
核心结论
- 本文旨在将已发表的关键研究结果置于临床背景中,帮助读者更好地将包括《临床肿瘤学杂志》所发表研究在内的结果应用于自己的临床实践。
研究设计与样本
- 本文为肿瘤学大查房系列文章,通过病例展示、诊断与管理挑战描述、相关文献综述及作者建议的管理方法总结来组织内容。
主要发现
- 第一例患者为56岁健康绝经后女性,左乳1点钟位置可触及肿块,活检证实乳腺癌后行乳房切除术和腋窝淋巴结清扫,肿瘤3.5cm,广泛脉管侵犯,病理为低分化3级浸润性导管癌及导管原位癌(最大灶3.5cm),切缘阴性,11枚腋窝淋巴结中2枚转移,雌激素受体表达50%阳性、孕激素受体阴性、Ki-67评分60%,人表皮生长因子受体2/neu基因无扩增,分期扫描无转移性疾病。
- 第二例患者为52岁绝经后女性,右乳可触及肿块,核心活检证实乳腺癌后行象限切除术和腋窝淋巴结清扫,最终病理为中分化浸润性导管癌(直径2.5cm),切缘阴性,3枚前哨淋巴结均无转移,雌激素受体表达90%阳性、孕激素受体表达40%阳性、Ki-67评分20%,人表皮生长因子受体2/neu基因无扩增,分期扫描无转移性疾病,基因组检测提示中至高复发风险,既往有高血压和体重中度超重(体重指数39 kg/m2)。
- 两例患者的多学科肿瘤委员会均推荐辅助化疗、术后放疗和内分泌治疗。
临床怎么用
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A healthy 56-year-old postmenopausal woman discovered a palpable mass at the one o'clock position of the left breast. After an initial biopsy confirmed breast cancer, she underwent mastectomy and axillary node dissection for a left-sided breast cancer that measured 3.5 cm. There was extensive lymphovascular invasion. Pathology review indicated a poorly differentiated, grade 3 invasive ductal carcinoma and ductal carcinoma in situ (largest focus, 3.5 cm). The margins were negative. Two of the 11 axillary lymph nodes contained metastatic carcinoma. Immunohistochemical studies previously obtained on the core biopsy indicated that the tumor was positive for estrogen receptor expression (50%), negative for progesterone receptor expression, and had a Ki-67 score of 60%. There was no amplification of the human epidermal growth factor receptor 2/ neu gene. Staging scans were negative for metastatic disease. Our multidisciplinary tumor board recommended adjuvant chemotherapy, postmastectomy radiation therapy, and endocrine therapy. A 52-year-old postmenopausal woman presented with a palpable mass of the right breast. An initial core biopsy confirmed carcinoma in the breast. She underwent quadrantectomy and axillary node dissection. The final pathology report disclosed a moderately differentiated invasive ductal carcinoma (diameter, 2.5 cm). The margins were negative. None of the three sentinel lymph nodes contained metastatic carcinoma. Immunohistochemical studies showed that the tumor was positive for estrogen receptor expression (90%) and for progesterone receptor expression (40%) and had a Ki-67 score of 20%. There was no amplification of the human epidermal growth factor receptor 2/ neu gene. Staging scans were negative for metastatic disease. A genomic assay was obtained and suggested an intermediate to high risk of recurrence. Her past medical history was notable for hypertension and moderately overweight status (body mass index, 39 kg/m2). Our multidisciplinary tumor board recommended adjuvant chemotherapy, postsurgical radiation therapy, and endocrine therapy.
引用
- Curigliano G, Criscitiello C. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. J Clin Oncol. 2017. PMID: 28661760. doi:10.1200/JCO.2017.72.5960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。